latanoprost/netarsudil (Rocklatan)

Introduction

FDA approved April 2019.

latanoprost 0.005% / netarsudil 0.02%

Indications

• open-angle glaucoma

Dosage

• one drop in affected eye(s) QHS

Clinical significance

• may be more effective in lowering intraocular pressure than either agent alone

Mechanism of action

• see latanoprost & netarsudil

More general terms

• pharmacologic combination

Components

• latanoprost (Xalatan)
• netarsudil (Rhopressa)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=118984471